Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   December 2013
 
A LA UNE
12/13/2013 - "Drug-Resistance & Innovation", a featured topic during the 5th Hospital-Acquired Infections Day

In partnership with the Finovi Foundation, Lyonbiopole organizes an annual event dedicated to Hospital-Acquired Infections. The fifth edition was held on Friday 13 December in Lyon and addressed innovation and drug-resistance issues. Eleven conferences marked the event, providing opportunities for speakers of all profiles: large companies, SMEs, academics and clinicians presented their approaches to an audience of over 100 participants.
Contact: Sarah Crochon, Clinical Project Manager – Sepsis Program - sarah.crochon@lyonbiopole.com


12/06/2013 - Success for the 5th edition of the Lyonbiopole's Private Inv€stment Day

More than 120 participants were present at Lyonbiopole's Private Invstiments Day, organized this year in collaboration with Bpifrance, CREALYS, GRAIN, NOVACITE and le Pôle d'Orientation Financière Rhône-Alpes with support from Sanofi-Pasteur. This event dedicated to SMEs and private investors was divided in 3 highlights: breakfast investors that enabled 10 SMEs to present their project to a pannel of 24 investors, a presentation from Bpifrance of its new tools for financing innovation and a roundtable on Family Offices and Fund Corporate Ventures. A busy day that ended with a networking lunch.
Contact: Kevin Romani, SMEs’ Development Director - kevin.romani@lyonbiopole.com

Learn more


11/07/2013 - Lyonbiopole opens its platform for innovation "Accinov"

On November 7th, under a bright sun, Gérard Collomb, Jean-Jack Queyranne, Philippe Archinard, Alexis Perret inaugurated the new building of the Accinov platform, in the presence of Jean-François Carenco and Philippe Chêne and with the participation of Alain Mérieux and Christopher Viehbacher. With the only such platform in Europe, Accinov sets the standard for innovative start-up parks. It is designed for biotech companies developing breakthrough technologies and innovative products and services. Accinov provides ready-to-use clean room labs offering bio-safety level (BSL) 2 facilities, as well as support services for advanced technology activities (bio-production, bio-analysis...).
Contact: Stéphanie Colloud, Accinov General Manager - stephanie.colloud@accinov.com

Learn more



ZOOM SUR
EVEON

Eveon, Lyonbiopole's member, is designer and manufacturer of innovative digital medical devices for the preparation and/or the automatic administration of drugs. Eveon proposes customized solutions which exactly meet the needs of its customers. The group Eveon strongly boosted its development in 2013 with 26 collaborators, by reaching a turnover of 2M€ from which more than 90 % are realized in export. It has delivered its first devices for clinical trials and is currently finalizing 2 major contracts : a co-patent agreement with a European Mid-Pharma industry, which concerns a process of reconstruction of a lyo drug already marketed and joint-development agreement for an injection device dedicated to precise injections at the hospital during surgery.

Learn more



A LA UNE
02/11/2014 - Role of modeling and data analysis in healthcare products development meeting

On February 11th 2014, INRIA, in partnership with Lyonbiopole, organizes in Lyon an INRIA-Industry meeting, dedicated to the role of modeling and data analysis and management in the conception of new drugs and healthcare products. Speakers from industry, academia and healthcare professionals will share their experience and provide an overview. Demos from INRIA teams and other Lyonbiopole members will be on display in the showroom. Bioinformatics, "omics" data analysis, bio-modeling, HPC and Big-Data will be among the addressed topics.
Contact: Claudia Chagneau, R&D Projects Manager - claudia.chagneau@lyonbiopole.com

Learn more


04/10/2014 - Participate to the "2014 CASyM academic/industry interaction workshop"

Lyonbiopole is participating to a European Coordinated Action on Systems Medicine CASyM, aiming at developing a roadmap for Systems Medicine implementation across Europe. This roadmap is used by the European Commission to help define the calls of its Horizon 2020 program. The CASyM roadmap is updated through a series of workshops (2012-2016).
  • Participate to the "2014 CASyM academic/industry interaction workshop" in Lyon (France) – April 10th  2014. Register here. To be able to present your innovative technological offers or R&D collaborative project idea, complete the form.
  • Contribute to the online survey on present and future research needs in systems biology.
Contact: Estelle Vincent, Project Manager - estelle.vincent@lyonbiopole.com

04/28-05/02/2014 - Participate to the Collective mission to Boston during Bio-IT

Lyonbiopole is pleased to invite you to participate to the collective mission organised with the French health and ICT clusters to be held from April 28th to May 2nd, 2014 in Boston during the Bio-IT convention. This mission is between Health / Engineering Sciences around e-health/ICT topics and will be organized on the occasion of the Bio-IT International Convention in Boston. The mission, programme will be split into 2 key moments: access to Bio-IT convention in Boston (April 29th/ May 1st, 2014), appointment collective or semi-collective Key Accounts: R&D centers, industry in the Boston area (April 28th and May 2nd, 2014).
Contact: Kevin Romani, SMEs’ Development Director - kevin.romani@lyonbiopole.com

Learn more


06/5-6/2014 - Save the date : 9th  BIOVISION edition

BIOVISION, the World Life Sciences Forum, in Lyon will be held from 5th to 6th June 2014 in Lyon. BIOVISION will be organized around several key points :
  • An opening plenary session on the theme of "Disruptive Innovation"
  • Two plenary prospective sessions around the focuses "Vaccination for all" and "Healthy ageing"
  • Two Catalyzer sessions, allowing innovative collaborative projects selected to benefit from visibility and meet potential public-private partners.
  • Investor Conference, a high-level investor conference allows selected biotech, medtech and e-health start-up companies to present and to meet the health sector decision-makers and potential public and private investors.
Contact: Kevin Romani, SMEs’ Development Director - kevin.romani@lyonbiopole.com


AGENDA
42nd International Congress on Intensive Care Medicine
January  15th to 17th 2014 - Paris, France
Bio-Europe Spring 2014
March 10th to 12 th 2014 -Turino, Italia
Bio-IT world Conference & Expo'14
April 29th to may 1st 2014 - Boston, US
The 16th Shanghai International Forum on Biotechnology and Pharmaceutical Industry
May 21th to 23th 2014 - Shanghai, China
BIO 2014
June 23th to 26th 2014 - San Diego, US
 
A LA UNE
12/11/2013 - Publication of the 1st Horizon 2020 calls for projects

The European Commission has published on December 11th 2013 the first Horizon 2020 calls for projects, the new European funding program for research and innovation with a budget of €80 billion, of which more than 15 billion euros for the first two years. The program has three pillars: scientific excellence, nearly 3 billion euros planned, including 1.7 billion for grants for top researchers; industrial leadership: € 1.8 billion are provided to support the industrial leadership of Europe in areas such as biotechnology, nanotechnology, and the societal challenges: € 2.8 billion is dedicated for innovative projects on the 7 social issues including H2020 health. Find all calls on the official portal.
Lyonbiopole supports you for EU project set-up thanks to its ETP programme.
Contact: Emilie Romeo - Project Manager - emilie.romeo@lyonbiopole.com

Learn more


12/02/2013 - Innovation 2030 Worldwide Innovation Challenge

The Innovation 2030 Commission, chaired by Anne Lauvergeon has defined  seven major ambitions relying on strong, growing, societal expectations, for which innovative solutions are needed. Among these pillars for France's future development is Personalised medicine. The Innovation 2030 Worldwide Innovation Challenge will include 3 phases. The Start-up Phase is opened and will end when 100 innovative projects will be selected. The expected projects must be supported by individual company or consortia. The selected projects must show a strong potential for French economy and correspond to one of the seven goals. The selected project receive a financial subsidy which can reach 200 000 €.
Contact: Claudia Chagneau, R&D Projects Manager - claudia.chagneau@lyonbiopole.com

Learn more


10/2013 – 10th and 11th calls for projects IMI open

The IMI programme launches 10 and 11th calls for projects. The 10th call is on infectious diseases: "Immunological assay standardization and development for use in assessments of Correlates of protection for influenza vaccines" (deadline: 28.01.2014). The 11th call covers several major research themes cut into 8 topics around the effective use of biomarkers and biobanks for personalized medicine, preparation and prevention of zoonoses, prevention of Alzheimer's disease (filing date: 08/04 / 2014). Several webinars are organized.
Lyonbiopole supports you for EU project set-up thanks to its ETP programme.
Contact: Emilie Romeo - Project Manager - emilie.romeo@lyonbiopole.com

Learn more


10/2013 - New Eurostars 2 call for projects

After the success of the 1st Eurostars programme, the EC launches Eurostars 2. This funding programme is fully dedicated to innovative SMEs aiming to launch R&D projects closed to the market, that are collaborative and European (at least 2 partners from EU). The funding rate for projects goes from 30 to 40% (subsidy managed by BPI France). Thus the new Eurostars 2 call for project is launched, which submission deadline is planned on March 13, 2014. Lyonbiopole supports you for EU project set-up thanks to its ETP programme.
Contact: Emilie Romeo - Project Manager - emilie.romeo@lyonbiopole.com

Learn more



A LA UNE
11/26/2013 - Lyonbiopole sets sights on Horizon 2020


Lyonbiopole and its partners, including University Claude Bernard and Hospices Civils de Lyon held on November 26 in Lyon, an information day about Horizon 2020 and Health topics, with the national contact points. This event brought together over 120 participants, nearly half from SMEs and large groups. The cluster also co-organized an info day on Eurostars 2 program alongside ARDI on December 10. These actions, carried out under Lyonbiopole’s  ETP aim to mobilize Rhône-Alpes health actors to strengthen their participation in European projects. The Cluster also supports its members to search partners thanks to its network of European Health Clusters. Thus, during 2014 communication activities will be carried out on the various funding programs for the benefit of members.
Contact: Emilie Romeo – Project manager emilie.romeo@lyonbiopole.com

11/22/2013 - A first workshop in oncology co-animated by Lyonbiopole and the CLARA

The two Clusters organized a workshop on the Valorisation of oncology research during the 6th French Oncology Meetings, on November 6 and 7. This workshop provided an update on the latest developments, remaining challenges and expected progress margins. On this occasion, the operational collaboration between the Cancer Cluster and the Competitiveness Cluster, for the first time in France, was highlighted.
Contact: Claudia Chagneau, R&D Projects Manager - claudia.chagneau@lyonbiopole.com

12/12/2013 - Calixar, a rising star

CALIXAR has been awarded the 2013 Innovation Prize from Rhône County. This prize rewards a company among the best start-ups followed by the Lyon University Foundation and the Lyon’s Chamber of Commerce, which meets the following selection criteria: innovation, financial strength and Organization viability, social and environmental interest.

Learn more


12/09/2013 - Valneva Secures $ 30M new financing and confirms sale of clinical manufacturing operations in France

European Biotechnology company Valneva SE (Valneva) today announced that it has secured a USD 30 million financing from an investment fund managed by Pharmakon Advisors for its Autrian subsiadiary Valneva Austria GmbH. It also confirmed that it has recently finalized the sale of its Clinical Manufacturing Operations (CMO) in Nantes, consisting in the transfer of the facility along with 22 Valneva employees.

Learn more


12/09/2013 - Endocontrol raises € 4 million

This innovative French start-up company designer of new generation robotic assistance systems for surgery closed, a € 4 million financing round, which will accelerate its technological and commercial development to impose its two robots ViKY and JAiMY.

Learn more


12/09/2013 - Exclusive license on a nanotechnology

Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors.This new technology, was developed by Professor Sébastien Lecommandoux and his team at the Laboratoire de Chimie des Polymères Organiques. It is remarkably efficient in carrying active molecules and delivering them within solid tumor.

Learn more


11/13/2013 - Oncodesign and UCB signed a research agreement

Oncodesign and UCB enter into a research collaboration for the early development of new therapeutic agents in neurodegenerative diseases.This partnership is based on Nanocyclix(R) platform of Oncodesign for new generation kinase inhibitor and on the expertise of UCB Neurology.

Learn more


11/11/2013 - ERYTECH announces positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia

ERYTECH Pharma announces that an independent Data and Safety Monitoring Board (DSMB) completed its first assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) study and unanimously recommended continuation of the trial without modification.

Learn more


11/04/2013 - Imaxio and VitamFero launch R&D partnership

Under the terms of this agreement, the two companies will evaluate the benefit of combining IMX313, Imaxio pro-immunogenic technology, VitamFero attenuated live parasites for vaccine development.

Learn more


10/30/2013 - ABL, Inc. announced a co-marketing agreement with CALIXAR SAS

Under the terms of the agreement, ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re-folding and mutagenesis, while maintaining functionality, structural integrity and increasing product yield.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |